Yutrepia's maker, Liquidia, has scheduled a first commercial shipment of the PH therapy to be available at specialty ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

The FDA has endorsed plans for a Phase 2b clinical trial that will test CS1, Cereno Scientific's experimental treatment for ...

Low-dose metformin delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of PAH in rats.

The ultrasound catheter is being tested in the PreVail-PH2 study, an early feasibility trial enrolling PH patients with left ...

The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of ...

Pulmonary hypertension (PH) is a rare, life-threatening disease that affects the pulmonary arteries, the lungs, and the heart. Patients who suffer from the disease have narrow and obstructed pulmonary ...

Six out of 10 people with pulmonary arterial hypertension who were followed for 10 years in an extension study are still ...

Reducing the levels of the protein NEK2 in the pulmonary arteries lessened disease-driving changes in blood vessels and the heart of a rat model of pulmonary arterial hypertension (PAH) due to ...